Eva Giné

8PUBLICATIONS

74CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Nutrigenomics and personalised nutritionPredictive and prognostic markersHaematological tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|Jul 14, 2026

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

|Jun 15, 2025

Therapy Sequencing in Relapsed/Refractory MCL.

Eva Giné

|Jun 20, 2024

Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.

Beatriz Rey-Búa, Carlos Grande, José J Sánchez Blanco

|Jan 14, 2022

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Eva Giné, Fátima de la Cruz, Ana Jiménez Ubieto

|Nov 30, 2021

The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma.

Pablo Mozas, Andrea Rivero, Alfredo Rivas-Delgado

|Nov 28, 2020

The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients.

Pablo Mozas, Marc Sorigué, Alfredo Rivas-Delgado

Pageof 2

Frequent Collaborators

6 joint publications

Armando López-Guillermo

Elías Campo

Ferran Nadeu

Neus Villamor

Alfredo Rivas-Delgado

Julio Delgado

Pablo Mozas

Laura Magnano

Juan Gonzalo Correa

Alex Bataller

Frequent Collaborators

6 joint publications

Armando López-Guillermo

5 joint publications

Elías Campo

4 joint publications

Ferran Nadeu

3 joint publications

Neus Villamor